CytoDyn Phase 2 study of leronlimab cleared by FDA

seekingalpha11-04

Iryna Drozd CytoDyn (OTCQB:CYDY) said the FDA has cleared a Phase 2 study of its drug leronlimab for the treatment of relapsed/refractory microsatellite stable colorectal cancer. Patient enrollment ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481531541?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387472103/image_1387472103.jpg","is_english":true,"pubTime":"2024-11-04 23:22","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2481531541","market":"sh","top_or_hot":-1,"title":"CytoDyn Phase 2 study of leronlimab cleared by FDA","media":"seekingalpha","content":"<div>\n<p>Iryna Drozd \nCytoDyn (OTCQB:CYDY) said the FDA has cleared a Phase 2 study of its drug leronlimab for the treatment of relapsed/refractory microsatellite stable colorectal cancer.\nPatient enrollment ...</p>\n\n<a href=\"https://seekingalpha.com/news/4242778-cytodyn-phase-2-study-of-leronlimab-cleared-by-fda\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CytoDyn Phase 2 study of leronlimab cleared by FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytoDyn Phase 2 study of leronlimab cleared by FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-04 23:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4242778-cytodyn-phase-2-study-of-leronlimab-cleared-by-fda><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Iryna Drozd \nCytoDyn (OTCQB:CYDY) said the FDA has cleared a Phase 2 study of its drug leronlimab for the treatment of relapsed/refractory microsatellite stable colorectal cancer.\nPatient enrollment ...</p>\n\n<a href=\"https://seekingalpha.com/news/4242778-cytodyn-phase-2-study-of-leronlimab-cleared-by-fda\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/4242778-cytodyn-phase-2-study-of-leronlimab-cleared-by-fda","article_id":"2481531541","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387472103/image_1387472103.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481531541","pubTimestamp":1730733742,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Patient enrollment for the study will begin in early 2025. The study will be conducted with Syneos Health.“This milestone reflects the continued positive development of the company’s improved relationship with the FDA,” CytoDyn said in a statement.Shares of CytoDyn rallied in February after the company announced the FDA had lifted a clinical hold on leronlimab.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CYDY":"CytoDyn Inc."},"translate_title":"leronlimab的Cytodyn 2期研究获FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYDY":0.9},"content_text":"Iryna Drozd \nCytoDyn (OTCQB:CYDY) said the FDA has cleared a Phase 2 study of its drug leronlimab for the treatment of relapsed/refractory microsatellite stable colorectal cancer.\nPatient enrollment for the study will begin in early 2025. The study will be conducted with Syneos Health. \n“This milestone reflects the continued positive development of the company’s improved relationship with the FDA,” CytoDyn (OTCQB:CYDY) said in a statement.\nShares of CytoDyn (OTCQB:CYDY) rallied in February after the company announced the FDA had lifted a clinical hold on leronlimab.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481531541"}